Here’s whether AstraZeneca PLC (AZN) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bearish.
🔴
Bearish
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-2.80% over 10 days); 3-month momentum negative (-13.8%); rising volume on a downtrend (distribution, 1.47x avg). Currently 26.4% off its 52-week high. Score: -5/7.
AZN is trading below its 200-day MA ($184.35) — a key warning sign the longer-term trend is under pressure. An RSI of 30.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -0.3% compares to +20.4% for SPY (trailed the market by 20.7%). The current 26.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.
$10,000 invested 1 year ago→ $9,969 today
vs. S&P 500 (SPY) — same period trailed market by 20.7%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✗Above 200-day MA ($184.35)
✗Above 50-day MA ($174.14)
✓RSI(14) neutral zone (30–70) — currently 30.6
✗Positive return (-0.3%)
!Within 10% of period high (−26.4%)
Period Range $156.45
$145.79$212.71
RSI (14) 30.6
0 · OversoldOverbought · 100
Key Metrics
Price$156.45
Period Return-0.3%
Period High$212.71
Period Low$145.79
Drawdown−26.4%
MA-50$174.14
MA-200$184.35
RSI (14)30.6
Avg Volume (30d)3.8M
vs. SPYtrailed by 20.7%
Return Rank#690 of 1252
Trend Signals
Price is below the 200-day moving average ($184.35)
Price is below the 50-day moving average ($174.14)